Sumatriptan Succinate Tablet, Film Coated
Product Images NDC 0378-5632

6 FDA label images from Mylan Pharmaceuticals Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Sumatriptan Succinate (NDC 0378-5632). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Sumatriptan Structural Formula (Image 01)

Sumatriptan Structural Formula (Image 01)
Chemical structure of sumatriptan succinate, showing the molecular components and bonding arrangement of the active ingredient.*
FDA Label Image

Figure 1. Estimated Probability Of Achieving Initial Headache Response Within 4 Hours Of Treatment In Pooled Trials 1, 2, And 3a (Image 02)

Figure 1. Estimated Probability Of Achieving Initial Headache Response Within 4 Hours Of Treatment In Pooled Trials 1, 2, And 3a (Image 02)
A line graph depicting the estimated probability of response over time in minutes from the initial dose for sumatriptan succinate tablets at 25 mg, 50 mg, 100 mg, and placebo. The graph shows increasing response probabilities for all doses except placebo, which remains lower over 240 minutes.*
FDA Label Image

Figure 2. The Estimated Probability Of Patients Taking A Second Dose Of Sumatriptan Tablets Or Other Medication To Treat Migraine Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Trials 1, 2, And 3a (Image 03)

Figure 2. The Estimated Probability Of Patients Taking A Second Dose Of Sumatriptan Tablets Or Other Medication To Treat Migraine Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Trials 1, 2, And 3a (Image 03)
A line graph depicting the estimated probability of remedication or rescue over 24 hours from the initial dose, comparing placebo and sumatriptan succinate tablets at 25 mg, 50 mg, and 100 mg strengths. The x-axis represents time in hours, and the y-axis shows probabilities from 0% to 100%.*
FDA Label Image

Sumatriptan Tablets 25 mg Bottle Label (Image 04)

Sumatriptan Tablets 25 mg Bottle Label (Image 04)
Sumatriptan 25 mg film-coated tablets by Mylan Pharmaceuticals Inc. The label shows a package of 9 tablets with the NDC 0378-5630-59. It includes dispensing and storage instructions, emphasizing keeping the medication out of children's reach and protecting from light and heat, along with directions to swallow tablets whole without splitting.*
FDA Label Image

Sumatriptan Tablets 50 mg Bottle Label (Image 05)

Sumatriptan Tablets 50 mg Bottle Label (Image 05)
Label for Sumatriptan tablets, USP, 50 mg film-coated tablets by Mylan Pharmaceuticals Inc. The label shows a blister pack with markings 'M' and 'S7'. The package contains 9 tablets, with prescription use only. It includes handling and storage instructions, a barcode, and a note on the active ingredient content equivalent to 50 mg sumatriptan per tablet.*
FDA Label Image

Sumatriptan Tablets 100 mg Bottle Label (Image 06)

Sumatriptan Tablets 100 mg Bottle Label (Image 06)
Sumatriptan Tablets, USP 100 mg film-coated tablets label from Mylan Pharmaceuticals Inc. The label states each tablet contains 140 mg of sumatriptan succinate, USP equivalent to 100 mg of sumatriptan. The package contains 9 tablets and is Rx only. Instructions include storage between 20° to 25°C (68° to 77°F), protection from light, and dispensing in a light-resistant container with a child-resistant closure.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.